$1.13
-0.09[-7.38%]
At close: May 17
$1.13
0[0.00%]
After Hours: 4:01PM EDT
Alaunos Therapeutics
(NASDAQ:TCRT)Alaunos Therapeutics Stock (NASDAQ:TCRT), Analyst Ratings, Price Targets, Predictions
Alaunos Therapeutics Inc has a consensus price target of $1.8, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Laidlaw & Co., and HC Wainwright & Co. on August 16, 2023, August 15, 2023, and May 15, 2023. With an average price target of $0.5 between HC Wainwright & Co., Laidlaw & Co., and HC Wainwright & Co., there's an implied -55.75% downside for Alaunos Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Laidlaw & Co.
Wells Fargo
Wells Fargo
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Alaunos Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 08/16/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth | — | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | Buy Now | — | Laidlaw & Co. | Yale Jen | — | Downgrade | Buy → Hold | Get Alert |
| 05/15/2023 | Buy Now | 32.74% | HC Wainwright & Co. | Swayampakula Ramakanth | → $22.5 | Upgrade | Neutral → Buy | Get Alert |
| 03/27/2023 | Buy Now | 165.49% | Wells Fargo | Yanan Zhu | → $45 | Assumes | → Overweight | Get Alert |
| 10/04/2022 | Buy Now | 165.49% | Wells Fargo | Nick Abbott | → $45 | Assumes | → Overweight | Get Alert |
| 07/15/2022 | Buy Now | 165.49% | Cantor Fitzgerald | Prakhar Agrawal | → $45 | Assumes | → Overweight | Get Alert |
| 05/04/2022 | Buy Now | 165.49% | Wells Fargo | Nick Abbott | → $45 | Upgrade | Equal-Weight → Overweight | Get Alert |
FAQ
What is the target price for Alaunos Therapeutics (TCRT)?
The latest price target for Alaunos Therapeutics (NASDAQ: TCRT) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $0.00 expecting TCRT to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alaunos Therapeutics (TCRT)?
The latest analyst rating for Alaunos Therapeutics (NASDAQ: TCRT) was provided by HC Wainwright & Co., and Alaunos Therapeutics downgraded their neutral rating.
When was the last upgrade for Alaunos Therapeutics (TCRT)?
The last upgrade for Alaunos Therapeutics Inc happened on May 15, 2023 when HC Wainwright & Co. raised their price target to $1.5. HC Wainwright & Co. previously had a neutral for Alaunos Therapeutics Inc.
When was the last downgrade for Alaunos Therapeutics (TCRT)?
The last downgrade for Alaunos Therapeutics Inc happened on August 16, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Alaunos Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Alaunos Therapeutics (TCRT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alaunos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alaunos Therapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating Alaunos Therapeutics (TCRT) correct?
While ratings are subjective and will change, the latest Alaunos Therapeutics (TCRT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Alaunos Therapeutics (TCRT) is trading at is $1.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.